All In MedTech

Device Trial Radar · NCT03326804

H1 Hip Resurfacing Arthroplasty

A Prospective, Non-randomized, Consecutive Series, Multicentre, Observational Study to Evaluate the Clinical Outcome of ceramic-on- Ceramic Hip Resurfacing Arthroplasty Using the Ceramic, Non-porous, Non-cemented H1 Hip Resurfacing Arthroplasty

Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Sep 26, 2017

Primary completion

Mar 17, 2032

Study completion Mar 25, 2033

Sponsor

Lead sponsor
Embody Orthopaedic LimitedNot on our public-company list
Sponsor type
Industry
Collaborators
Imperial College London
First posted
Oct 31, 2017

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, non-randomized, consecutive series, multicentre, observational study to evaluate the clinical outcome of ceramic-on- ceramic hip resurfacing arthroplasty using the ceramic, non-porous, non-cemented H1 Hip Resurfacing Arthroplasty. It includes a safety study followed by an efficacy study. Patients will be followed up for 10-years postoperatively. The primary aim is to confirm the safety of the H1 hip resurfacing prosthesis by demonstrating non-inferiority of the H1 device in terms of survivorship. The secondary is to evaluate superiority of the ceramic-on-ceramic H1 hip resurfacing prosthesis compared to Metal-on-Metal (MoM) hip resurfacing in terms of absence of metal ion release.The primary end point is revision for any reason.

Conditions

  • Hip Osteoarthritis
  • Hip Necrosis
  • Hip Dysplasia

Interventions

  • H1 Hip Resurfacing ArthroplastyDevice

    A non-porous non-cemented ceramic-on-ceramic hip resurfacing arthroplasty device

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Oxford Hip ScoreTime frame: 10 years
  2. EQ-5D Health-Related Quality of Life QuestionnaireTime frame: 10 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Charing Cross Hospital

    London, United Kingdom

  • Kind Edward VII's Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.